Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KALA BIO, Inc. Director's Dealing 2017

Jul 19, 2017

35091_dirs_2017-07-19_ea2bc1f2-252d-4f7b-8897-0bb7be8ba29b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: Reumuth Mary (Chief Financial Officer, 10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $2.30 2024-10-02 Common Stock (11520) Direct
Stock Option (right to buy) $2.30 2024-10-02 Common Stock (11520) Direct
Stock Option (right to buy) $2.30 2024-12-04 Common Stock (15360) Direct
Stock Option (right to buy) $5.21 2025-10-02 Common Stock (5077) Direct
Stock Option (right to buy) $3.34 2026-06-17 Common Stock (92096) Direct

Footnotes

F1: This option was granted on October 2, 2014 and vests over four years, with 25% of the shares underlying the option vested on February 3, 2015, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

F2: This option was granted on October 2, 2014 and vests over four years, with to 25% of the shares underlying the option vested on August 18, 2015, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

F3: This option was granted on December 4, 2014 and vests over four years, with 25% of the shares underlying the option vested on December 4, 2015 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

F4: This option was granted on October 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on October 2, 2016, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

F5: This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vested on June 17, 2017, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.